Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of alarelin acetate microspheres in premenopausal hormone receptor-positive breast cancer
CTR20263903Phase 2Active
- Sponsor
- Lijun Pharmaceutical
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of alarelin in breast cancer, sponsored by Lijun Pharmaceutical. Started Oct 2026; status: active.
02
Drugs
alarelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20263903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263903.